Aged 25-65 years old Female and male patients Diagnosed with bilateral symmetrical Hori'
Conditions
Interventions
Each patient is treated by platelet-rich plasma injections on one side of the face every 2 weeks for four sessions ,Each patient is treated by normal saline on the other side of the face every 2 weeks
Active Comparator Other,Placebo Comparator Other
platelet-rich plasma injections ,normal saline
Sponsors
Institute of Dermatology, Bangkok, Thailand
Institute of Dermatology, Bangkok, Thailand
Eligibility
Sex/Gender
All
Age
25 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Patients aged 25-65 years old 2) Female and male patients 3) Diagnosed with bilateral symmetrical Hori'nevus 4) Can attend and be willing to be a subject in this study, including being able to give consent
Exclusion criteria
Exclusion criteria: 1) In the period of pregnancy or lactation 2) Have a history of acute allergic reaction to platelet-rich plasma 3) Having bleeding disorders such as Thalassemia or low platelets of less than 100,000 cells/uL 4) Having a blood-borne disease 5) Having a history of taking oral antioxidants such as vitamin C, vitamin E, or chemotherapy or any thrombolytic agent within 3 months before the study 6) Have a laser or IPL treatment on the face within 3 months before the study 7) Using whitening agents or chemical peeling agents within 3 months before the study 8) Have a history of platelet-rich plasma injection within 3 months before the study 9) Have a history of other abnormality of pigmentation on the face, including post-inflammatory hyperpigmentation 10) Having skin injury or skin lesions on the area of platelet-rich plasma injection, such as atopic dermatitis, infections, skin cancer, or dermatitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hori's nevus severity At baseline, 8 weeks, 10 weeks, 14 weeks, 18 weeks modified Dermal Pigmentation Area and Severity Index (mDPASI) | — |
Secondary
| Measure | Time frame |
|---|---|
| Melanin measurements At baseline, 8 weeks, 10 weeks, 14 weeks, 18 weeks Melanin index,Brightening of the lesion At baseline, 8 weeks, 10 weeks, 14 weeks, 18 weeks Brightening score,Patient satisfaction 8 weeks, 10 weeks, 14 weeks, 18 weeks Patient satisfaction score,Side effects At baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 14 weeks, 18 weeks Side effects report | — |
Countries
Thailand
Contacts
Public ContactChumsaeng Chumsaengsri
Institute of Dermatology
Outcome results
None listed